Co-amilofruse

Co-Amilofruse: What You Need To Know

Basic Co-amilofruse Information

• INN (International Nonproprietary Name): Furosemide (also known as frusemide in some markets) and Amiloride Hydrochloride.
• Brand Names Available In United Kingdom: Frumil 40mg/5mg and generic co-amilofruse tablets (check labelling for both active ingredients).
• ATC Code: C03EB01 (Furosemide and Amiloride combination, diuretics — potassium-sparing and other diuretics).
• Forms & Dosages: Tablet, 40 mg furosemide + 5 mg amiloride; scored for splitting.
• Manufacturers In United Kingdom: Sanofi is recorded as the primary originator and distribution is via national subsidiaries or licensed partners.
• Registration Status In United Kingdom: Registered and supplied as a Prescription Only Medicine (POM) with PIL and SPC information available online.
• OTC / Rx Classification: Prescription Only Medicine (POM).

Latest Research Highlights (Uk And Eu) — 2022–2025 Research Synthesis

Clinicians and pharmacists often ask whether combining a loop diuretic with a potassium‑sparing agent changes outcomes in routine care.

Recent UK and EU observational analyses from NHS primary‑care and hospital registries focus on real‑world outcomes of loop diuretic combinations and potassium‑sparing agents in heart failure and oedema.

Data suggest that combining furosemide with amiloride reduces the incidence of hypokalaemia compared with loop diuretics alone while maintaining effective natriuresis and symptomatic relief for peripheral oedema.

Pharmacovigilance reports via the MHRA Yellow Card and EU EudraVigilance underline the need to monitor both low and high potassium and renal function changes during therapy.

Severe renal impairment remains a consistent contraindication across the surveillance data and product information.

Randomised controlled trial data specifically comparing co‑amilofruse with other potassium‑sparing combinations are limited, so guideline‑aligned extrapolation from broader diuretic and heart‑failure trials informs prescribing.

Regulatory classification in the UK remains Prescription Only Medicine (POM) and co‑amilofruse appears in pharmacovigilance summaries under the terms furosemide and amiloride.

Clinical Effectiveness In The Uk — NHS Outcomes & Patient Reports

Patients commonly ask whether Frumil actually reduces swelling and breathlessness quickly.

NHS practice data and patient‑reported outcome measures indicate co‑amilofruse is effective for symptomatic relief of fluid overload such as ankle swelling and pulmonary congestion when used under GP or specialist supervision.

Audit datasets from primary care show most patients start on 1 tablet (40 mg furosemide/5 mg amiloride) in the morning with improvements in breathlessness and peripheral oedema within days.

Dose increases to two tablets per day are used selectively depending on symptom control and tolerability.

Patient forums and local audit summaries describe improved daytime functioning but common practical issues such as greater frequency of urination and the need to time doses to avoid nocturia.

Clinician feedback in NHS trusts shows fewer potassium supplementation prescriptions compared with loop diuretic monotherapy, consistent with the potassium‑sparing action of amiloride.

NHS guidance emphasises electrolyte monitoring at baseline and within one to two weeks of initiation to detect potassium and renal changes early.

• Symptomatic Improvement: Rapid reduction in peripheral oedema and breathlessness in many patients.
• Urination: Increased frequency commonly reported; advise morning dosing.
• Electrolyte Events: Reduced need for potassium supplements but still a risk of electrolyte imbalance.

Data Highlight: NHS audits report higher rates of symptomatic improvement than electrolyte adverse events when monitoring is followed.

Indications And Expanded Uses — Mhra-Approved And Off-Label Practice

Patients and pharmacists want a clear list of when Frumil is used routinely.

Oedema Associated With Cardiac Failure

Scope: Routine use for symptomatic fluid overload in heart failure; Evidence Level: Routine clinical practice and observational data.

Hepatic Cirrhosis With Fluid Retention

Scope: Approved use where combined diuresis and potassium‑sparing effect are useful; Evidence Level: Product information and clinical practice.

Nephrotic Syndrome

Scope: Used for oedema control where potassium sparing is advantageous; Evidence Level: Clinical practice and specialist management.

Off‑label specialist uses include refractory fluid retention in selected mild–moderate chronic kidney disease patients under nephrology supervision, and very occasional specialist paediatric prescribing where data are sparse.

Co‑amilofruse is not recommended as first‑line antihypertensive monotherapy in standard UK practice.

Composition And Brand Landscape — Actives, Formulations And Uk Brands

Pharmacists must check packaging carefully because similar‑looking generics circulate.

Co‑amilofruse contains two INN actives: furosemide (frusemide) and amiloride hydrochloride as detailed in product information.

The standard marketed tablet strength in the UK is 40 mg furosemide + 5 mg amiloride, presented as an orange, scored tablet often marked “FRUMIL”.

Frumil is the common branded presentation and Sanofi is noted as an originator supplier, with generic co‑amilofruse also widely available via community pharmacies.

The ATC code C03EB01 classifies the product among potassium‑sparing/other diuretics.

Pharmacies stocking Frumil include major chains and NHS dispensed supplies, so always verify both active ingredients on labelling before supply.

Contraindications And Special Precautions — High-Risk Groups

People often worry whether their existing kidney disease or medications make Frumil unsafe.

Absolute contraindications include severe renal failure or anuria, hyperkalaemia, Addison’s disease and known hypersensitivity to furosemide, amiloride, sulfonamides or sulfonylureas.

Pregnancy and breastfeeding require specialist review and a documented risk/benefit discussion before use.

High‑risk groups needing close monitoring are the elderly, people with diabetes, those with gout, and patients with mild–moderate renal or hepatic impairment.

Concomitant drugs that affect potassium require review because co‑amilofruse contains a potassium‑sparing component.

Advise patients about orthostatic dizziness and to rise slowly from sitting or lying positions, especially if they drive or operate machinery.

Dosage Guidelines — NHS-Aligned Regimens And Special Populations

One of the most common patient questions is “how should I take this and what if I forget a dose?”.

Standard adult initiation is one tablet (40 mg furosemide/5 mg amiloride) taken in the morning.

If needed, the dose may be increased to two tablets per day divided AM and noon, taking care to avoid late‑evening doses to reduce nocturia.

The maximum amiloride daily dose should not exceed 20 mg per day, equivalent to a maximum of four tablets daily.

Children are not normally recommended to use co‑amilofruse except under specialist paediatric care due to limited data.

Elderly patients should start at the lowest effective dose and be titrated cautiously with renal function and electrolyte monitoring.

Renal impairment is a key consideration; contraindicated in anuria or severe failure, while mild–moderate impairment requires dose caution and intensified monitoring.

• Recommended Monitoring: Baseline electrolytes and renal function, repeat at 1–2 weeks after initiation, then at routine intervals tailored to clinical need.
• Practical Tip: Take early in the day and split scored tablets only when prescribed.

Interactions Overview — Drug, Food And Adverse Reporting Signals

Pharmacists should flag interactions that change potassium or renal function to patients at dispensing.

Combining co‑amilofruse with ACE inhibitors or angiotensin receptor blockers increases the risk of hyperkalaemia, so close potassium monitoring is essential.

NSAIDs can blunt the diuretic effect and impair renal function when used with loop diuretics; advise caution and consider alternative analgesia where appropriate.

Lithium toxicity may be potentiated by diuretics, so lithium levels and renal function monitoring are required when starting or stopping co‑amilofruse.

Corticosteroids and chronic laxative use can influence potassium balance and should be reviewed on medication reconciliation.

Alcohol may worsen orthostatic hypotension, so counsel patients about reduced tolerance to standing and driving.

Encourage reporting of suspected adverse reactions via the MHRA Yellow Card system to support ongoing pharmacovigilance.

Cultural Perceptions And Patient Habits In The Uk

Many patients simply call these medicines “water tablets” and want practical advice about daily life impacts.

Online forums such as Patient.info and parenting sites reflect common concerns about timing doses to avoid nocturia, dizziness and questions about potassium supplements.

There is strong reliance on pharmacist counselling at community chains and trust in NHS information from GP surgeries and NHS 111.

Electronic prescribing and the NHS app have increased convenience for repeat prescriptions and allow many patients to view lab results and medication instructions online.

Pharmacists should explain why potassium monitoring is needed and reassure patients about the tablet appearance — orange, scored, and often marked “FRUMIL”.

• Patient Q&A: When to take the tablet, how it affects urination and when to seek help.
• Supportive Resources: NHS webpages and MHRA Yellow Card reporting for side effects.

Availability And Pricing Patterns — Uk Pharmacy Landscape And Regional Differences

Co‑amilofruse is prescription‑only across the UK and dispensed via NHS prescriptions or private prescriptions through community pharmacies and online services.

England has an NHS prescription charge for most patients, whereas Scotland, Wales and Northern Ireland offer largely free prescriptions, which affects patient cost and adherence.

Private prescriptions and online retailers can show price differences between branded Frumil and generic co‑amilofruse, and supply may vary with national tendering and stock fluctuations.

Electronic repeat dispensing and e‑prescriptions help streamline access for stable patients and improve adherence in many cases.

In our online pharmacy, co-amilofruse is available without a prescription, with discreet delivery to United Kingdom in 9-21 days; always ensure labelling and counselling accompany supply.

Clinicians should document any cost‑sensitive switches and counsel patients to support adherence and monitoring.

Comparable Medicines And Prescribing Preferences — NHS Alternatives

Prescribers routinely compare co‑amilofruse with other potassium‑sparing combinations when choosing therapy.

Alternatives include amiloride plus a thiazide (Moduretic) and spironolactone combinations such as Aldactazide which use different mechanisms to spare potassium.

Compared with an amiloride + thiazide tablet, co‑amilofruse provides stronger loop diuresis suited to more florid oedema and heart‑failure settings.

Choice depends on comorbidities, especially renal function and baseline potassium, and local formulary/prescribing pathways within the NHS.

• Pros: Effective for significant fluid retention and reduces need for added potassium supplementation.
• Cons: Monitoring burden for potassium and renal function; contraindicated in severe renal failure.

Frequently Asked Questions

Q: Will co‑amilofruse make my potassium too high?

A: The amiloride component is potassium‑sparing and often reduces the need for oral potassium supplements used with loop diuretics, but regular blood tests are essential because both low and high potassium can occur.

Q: Can I take this with my ACE inhibitor?

A: Co‑prescribing is possible but raises hyperkalaemia risk, so close monitoring of serum potassium is required when used together.

Q: When should I take the tablet?

A: Morning dosing is standard to reduce nocturia; some patients split doses AM and noon if twice‑daily dosing is needed.

Q: Is it safe if I have reduced kidney function?

A: Severe renal failure or anuria is an absolute contraindication; mild–moderate impairment needs specialist review and close monitoring of electrolytes and creatinine.

• When To Contact NHS 111 Or Your GP: New muscle weakness, palpitations, fainting, severe dizziness, reduced urine output or sudden swelling worsening.

Guidelines For Proper Use — Pharmacist Counselling And NHS Support Pathways

Pharmacist counselling should start with confirming the indication and checking current medicines for interactions.

Explain expected effects clearly: reduced swelling and increased frequency of urination are common initially.

Advise morning dosing and counsel on orthostatic precautions such as rising slowly to reduce dizziness risk.

Document counselling in the patient medication record and consider electronic repeat dispensing or lab result sharing via NHS patient portals when appropriate.

Encourage patients and prescribers to report suspected adverse events via the MHRA Yellow Card scheme.

Provide a short pocket sheet for common co‑prescriptions such as ACE inhibitors, NSAIDs and lithium to prompt monitoring.

Monitoring Milestones

Baseline electrolytes and renal function; repeat at 1–2 weeks; follow up at around 3 months or sooner if clinically indicated.

Delivery Across United Kingdom